Clinical Trial VICCGI13104
A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
- Protocol No. VICCGI13104
- Open Date: 08/06/2014
- Staging: Phase II
- Age Group: Adults
- Scope: National
- Objective: To evaluate the investigator objective response rate (ORR) of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with metastatic MSI-H CRC.
- Disease Sites: Colon
- Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
- Drugs: Ipilimumab; Nivolumab (BMS-936558)
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: CA209142
Not provided. Please call for more information.